Equities Analysts Offer Predictions for PRE FY2025 Earnings

Key Points

• Equities analysts at Cantor Fitzgerald have increased their FY2025 earnings estimates for Prenetics Global to ($2.56) EPS, up from a previous forecast of ($2.71), while the consensus estimate stands at ($3.30) EPS.
• Prenetics Global reported a quarterly EPS of ($0.82), with a negative net margin of 87.92% and revenues of $17.68 million.
• The stock currently holds an average rating of "Buy" with a consensus price target of $9.00, and institutional investors own 25.01% of the company.

Prenetics Global Limited (NASDAQ:PRE - Free Report) - Stock analysts at Cantor Fitzgerald upped their FY2025 EPS estimates for Prenetics Global in a research report issued to clients and investors on Wednesday, September 17th. Cantor Fitzgerald analyst R. Osborn now anticipates that the company will earn ($2.56) per share for the year, up from their previous forecast of ($2.71). The consensus estimate for Prenetics Global's current full-year earnings is ($3.30) per share. Cantor Fitzgerald also issued estimates for Prenetics Global's FY2026 earnings at ($0.06) EPS.

Prenetics Global (NASDAQ:PRE - Get Free Report) last issued its quarterly earnings data on Friday, September 12th. The company reported ($0.82) earnings per share for the quarter. Prenetics Global had a negative return on equity of 31.05% and a negative net margin of 87.92%.The business had revenue of $17.68 million for the quarter. Prenetics Global has set its FY 2025 guidance at EPS.

Separately, Wall Street Zen raised shares of Prenetics Global to a "hold" rating in a research report on Saturday, July 5th. One research analyst has rated the stock with a Buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $9.00.

Prenetics Global Stock Down 1.7%

Shares of PRE stock traded down $0.22 during mid-day trading on Friday, reaching $12.18. The company's stock had a trading volume of 60,979 shares, compared to its average volume of 38,874. The company's 50 day simple moving average is $8.38 and its 200-day simple moving average is $6.97. Prenetics Global has a 12-month low of $3.09 and a 12-month high of $12.59. The firm has a market capitalization of $158.03 million, a PE ratio of -3.05 and a beta of 0.15.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Prenetics Global stock. Stevens Capital Partners bought a new stake in Prenetics Global Limited (NASDAQ:PRE - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 17,382 shares of the company's stock, valued at approximately $137,000. Stevens Capital Partners owned 0.13% of Prenetics Global as of its most recent filing with the Securities and Exchange Commission (SEC). 25.01% of the stock is owned by institutional investors.

About Prenetics Global

Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies.